A user is concerned about hair loss despite using finasteride for 6 months. Others suggest patience, noting visible regrowth and recommending a combination of finasteride and minoxidil.
The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factorslike inflammation and scalp tension might also contribute to hair loss.
The user experienced significant hair regrowth using finasteride alone over 6-7 months, despite initial side effects like reduced sexual desire and acne. They are considering reducing the dosage to manage side effects and have also used ketoconazole shampoo weekly.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.
A 35-year-old reported significant hair regrowth after six months of using daily oral finasteride (1mg), oral minoxidil (1.25mg), and topical minoxidil, with no major side effects except increased hair growth in unwanted areas. Noticeable improvements were seen around four months after starting finasteride.
The user has been using Finasteride 1mg daily for over 6 months, experiencing decreased shedding and denser hair, and is considering adding Minoxidil to their regimen. They also addressed a past vitamin D deficiency with supplements and are hopeful for continued hair regrowth.
Cold shock therapy may promote hair growth, but cold alone is not effective. Combining treatments like minoxidil, finasteride, cold showers, spicy foods, and exercise may enhance results.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.
The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.
Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
The user had four DHI hair transplants from 2021 to 2025, with the last one in August, and is concerned about the lack of hair thickening despite using treatments like finasteride and minoxidil. They are seeking advice on why these efforts aren't working.
DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.
The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.
The user has been using Minoxidil for 6 months and biotin for 2 months without seeing results and is considering starting finasteride due to receding hair at the right temple. Replies suggest starting finasteride and comment on the user's hairline.
Using a combination of topical minoxidil and finasteride, plus microneedling, to treat hair loss; the progress made by the original poster over 6 months; the potential for further results with longer use; and the possibility of seeking alternatives such as a hair transplant or system.
A user shared their successful hair regrowth journey using 1mg finasteride daily, 1ml minoxidil nightly, and weekly 1.5mm microneedling. They reported some side effects like reduced semen thickness but are satisfied with the results and recommend topical minoxidil over oral.
Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.
The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.